Search
Peter Molloy (left) and chairman William Garner founded Race Oncology in 2016 to commercialise Bisantrene. Photo: Attila Csaszar

Race challenges big pharma mindset

For many cancer sufferers, the side effects of traditional chemotherapy treatments can compound an already difficult situation.

Login

(existing subscribers)

The password field is case sensitive.
Request new password

Add your comment

Share Price

Closing price for the last 90 trading days
Source: Morningstar

Total Shareholder Return as at 28/09/18

1 year TSR5 year TSR
299thQueste Communications18%-1%
553rdG Medical Innovations Holdings-20%0%
673rdDawine-40%-6%
804thRace Oncology-72%0%
739 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Source: Morningstar

Share Transactions

28/08/18
$7k Bought
15/06/18
$24k Bought
26/04/18
$0 Other
Total value as at the date of the transaction
Source: Morningstar

Revenue

193rd↓Dawine$224k
194th↓Queste Communications$172k
195th-Race Oncology$170k
196th↓Oakajee Corporation$158k
197th↑G Medical Innovations Holdings$140k
239 listed industrial companies ranked by revenue.
Source: Morningstar

BNiQ Disclaimer